Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients

The synuclein gamma (SNCG) protein, a member of neuronal protein family synuclein, has been considered as a promising potential biomarker as an indicator of cancer stage and survival in patients with cancer. The present study was conducted to evaluate the prognostic value of SNCG in patients with es...

Full description

Saved in:
Bibliographic Details
Published in:Tumor biology 2014-12, Vol.35 (12), p.11871-11877
Main Authors: Tastekin, Didem, Kargin, Suleyman, Karabulut, Mehmet, Yaldız, Naile, Tambas, Makbule, Gurdal, Necla, Tatli, Ali Murat, Arslan, Deniz, Gok, Ali Fuat Kaan, Aykan, Faruk
Format: Article
Language:English
Subjects:
Adult
Aged
Biomedicine
Cancer Research
Clinical outcomes
Esophageal cancer
Esophageal Neoplasms - diagnosis
Esophageal Neoplasms - metabolism
Esophageal Neoplasms - mortality
Esophageal Neoplasms - therapy
Female
gamma-Synuclein - genetics
gamma-Synuclein - metabolism
Gene Expression
Humans
Immunohistochemistry
Male
Medical prognosis
Middle Aged
Neoplasm Metastasis
Patient Outcome Assessment
Prognosis
Proteins
Research Article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The synuclein gamma (SNCG) protein, a member of neuronal protein family synuclein, has been considered as a promising potential biomarker as an indicator of cancer stage and survival in patients with cancer. The present study was conducted to evaluate the prognostic value of SNCG in patients with esophageal carcinoma (EC). SNCG levels were assessed immunohistochemically in cancer tissues from 73 EC patients. Median age was 57 (range, 29–78) years old. Forty-seven percent of the patients were male. Thirty-seven percent of the patients had upper or middle localized tumor whereas 59 % had epidermoid carcinoma. More than half of the patients (61 %) had undergone operation where 57 % received adjuvant treatment including chemotherapy or chemotherapy plus radiotherapy. Median overall survival was 11.3 ± 1.8 months (95% confidence interval (CI): 7.7–14.9 months). SNCG positivity was significantly associated with the histological type of EC and inoperability (for SNCG positive vs. negative group; epidermoid 80 vs. 53 %; p  = 0.05 and inoperable 59 vs.32 %; p  = 0.04, respectively). Lymph node metastasis, inoperability and receiving no adjuvant treatment had significantly adverse effect on survival in the univariate analysis ( p  = 0.01, p  
ISSN:1010-4283
1423-0380
DOI:10.1007/s13277-014-2429-4